FEIBA: A Prohemostatic Agent

Caroline Cromwell; Louis M. Aledort

doi:10.1055/s-0032-1309286

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2012; 38(03): 265-267
DOI: 10.1055/s-0032-1309286

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

FEIBA: A Prohemostatic Agent

Authors

Caroline Cromwell

¹Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York
Louis M. Aledort

¹Division of Hematology/Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, New York

Abstract

Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac patients with inhibitors. The history of its use is reviewed here, including issues related to thrombosis, efficacy, and comparison to alternative bypassing agents. The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains.

Keywords

inhibitors - hemophilia - factor eight inhibitor bypassing activity - thrombosis

Full Text

References

References
1 Darby SC, Keeling DM, Spooner RJ , et al; UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2 (7) 1047-1054
2 Berntorp E, Shapiro A, Astermark J , et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12 (Suppl. 06) 1-7
3 Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291 (4) 164-167
4 Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5 (Suppl. 03) 11-17
5 Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83 (2) 137-143
6 Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61 (1) 36-40
7 Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77 (6) 1113-1119
8 Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12 (4) 352-362
9 Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15 (1) 3-10
10 Dargaud Y, Lienhart A, Meunier S , et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11 (5) 552-558
11 Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116 (25) 5734-5737
12 Klintman J, Astermark J, Berntorp E. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010; 151 (4) 381-386
13 Turecek PL, Váradi K, Keil B , et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33 (1) 16-22
14 Chavin SI, Siegel DM, Rocco Jr TA, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85 (2) 245-249
15 Fukui H, Fujimura Y, Takahashi Y, Mikami S, Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb Res 1981; 22 (1–2) 177-184
16 Schimpf K, Zeltsch C, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A. Lancet 1982; 2 (8306) 1043
17 Cederbaum AI, Blatt PM, Roberts HR. Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med 1976; 84 (6) 683-687
18 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 (3, Suppl 6) 3-5
19 Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8 (2) 83-90
20 Leissinger C, Gringeri A, Antmen B , et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365 (18) 1684-1692
21 Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10 (Suppl. 02) 3-9
22 Aledort LM. MedWatch: an important instrument for postlicensing surveillance. J Thromb Haemost 2006; 4 (7) 1637
23 Astermark J, Donfield SM, DiMichele DM , et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109 (2) 546-551
24 Ingerslev J, Sørensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 2011; 155 (2) 256-262